Program
daratumumab
Also written as “Daratumumab”, “Daratumumab SC” and “Daratumumab IV”.
Its studies are mostly in Multiple Myeloma · Amyloidosis · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Myelodysplastic Syndromes · Lymphoma, Mantle-Cell, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 284 open or running | phase 4since Nov 29, 2018 | Dec 14, 2007 | Jan 31, 2029phase 3 · NCT05438043 |
| Bristol-Myers Squibb | 31 open or running | phase 3since Aug 16, 2018 | May 12, 2016 | none ahead |
| Amgen | 10 open or running | phase 3since May 9, 2017 | May 9, 2017 | none ahead |
| Celltrion | 11 open or running | phase 3since Apr 29, 2025 | Apr 29, 2025 | Mar 8, 2027phase 3 · NCT06952478 |
Also a collaborator on its studies: Karyopharm Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Dec 14, 2007.
- Jun 27, 2017Phase 3 study in AmyloidosisJohnson & Johnson · NCT03201965 · 416 enrolled · United States, Australia, Belgium and more
- Jul 13, 20172 phase 3 studies in Multiple MyelomaJohnson & Johnson · NCT03217812, NCT03234972
- Sep 7, 2017Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT03277105 · 522 enrolled · United States, Australia, Brazil and more
- Dec 20, 2017Phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaJohnson & Johnson · NCT03384654 · 47 enrolled · United States, Belgium, France and more
- Aug 16, 2018Phase 3 study in Multiple MyelomaBristol-Myers Squibb · NCT03651128 · 386 enrolled · United States, Belgium, Canada and more
- Aug 17, 2018Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT03652064 · 395 enrolled · United States, Brazil, Canada and more
- Nov 29, 2018Phase 4 study in Multiple MyelomaJohnson & Johnson · NCT03768960 · 150 enrolled · India
- Apr 2, 2019Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT03901963 · 200 enrolled · United States, Canada
- Oct 8, 2019Phase 1 study in Multiple MyelomaJohnson & Johnson · NCT04121260 · 21 enrolled · China
- Nov 27, 2019Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT04181827 · 419 enrolled · United States, Australia, Belgium and more
- Feb 11, 2022Phase 2 study in AmyloidosisJohnson & Johnson · NCT05250973 · 151 enrolled · United States, Canada, China and more
- Jun 24, 2022Phase 3 study in Multiple MyelomaJohnson & Johnson · NCT05438043 · 214 enrolled · United States, Belgium, Brazil and more
- Aug 27, 2024Phase 2 study in Multiple MyelomaJohnson & Johnson · NCT06577025 · 43 enrolled · United States, Australia, Brazil and more
- Apr 29, 2025Celltrion's first study: phase 3 study in Multiple MyelomaNew to CelltrionCelltrion · NCT06952478 · 473 enrolled · Taiwan
Ahead
- Mar 8, 2027Primary completion: phase 3 study in Multiple MyelomaCelltrion · NCT06952478
- Jan 31, 2029Primary completion: phase 3 study in Multiple MyelomaJohnson & Johnson · NCT05438043
- Sep 2, 2030Primary completion: phase 2 study in Multiple MyelomaJohnson & Johnson · NCT06577025
TargetBeta
“A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities”NCIt, by rule
“Lymphocyte differentiation antigen CD38 inhibitor”ChEMBL 37, by rule
Other programs on CD38
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| isatuximabrule | Sanofi | phase 3 | 23 |
| felzartamabrule | Biogen | phase 3 | 15 |
| mezagitamabrule | Takeda | phase 3 | 11 |
| lumrotatugrule | Keymed Biosciences | phase 3 | 10 |
| Anti-CD38 Monoclonal Antibody SCTC21Crule | Sinocelltech Group | phase 3 | 5 |
| sanritatugrule | Hangzhou Sumgen Biotech | phase 3 | 5 |
| CID-103rule | CASI Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD38 Monoclonal Antibodyrule | Chongqing Genrix Biopharmaceutical | phase 2 | 1 |
| Anti-CD38 Antibody-drug Conjugate ABBV-438 | AbbVie | phase 1 | 1 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06952478Multiple Myeloma · Taiwan | 3 | Active, not recruiting | Celltrion | Mar 8, 2027 | 473 |
| NCT06577025Multiple Myeloma · United States, Australia, Brazil and more | 2 | Active, not recruiting | Johnson & Johnson | Sep 2, 2030 | 43 |
| NCT05438043Multiple Myeloma · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Johnson & Johnson | Jan 31, 2029 | 214 |
| NCT05250973Amyloidosis · United States, Canada, China and more | 2 | Active, not recruiting | Johnson & Johnson | Feb 4, 2026 | 151 |
| NCT04181827Multiple Myeloma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | May 1, 2024 | 419 |
| NCT04121260Multiple Myeloma · China | 1 | Completed | Johnson & Johnson | Apr 27, 2021 | 21 |
| NCT03901963Multiple Myeloma · United States, Canada | 3 | Completed | Johnson & Johnson | Apr 4, 2024 | 200 |
| NCT03768960Multiple Myeloma · India | 4 | Completed | Johnson & Johnson | Jul 16, 2022 | 150 |
| NCT03652064Multiple Myeloma · United States, Brazil, Canada and more | 3 | Completed | Johnson & Johnson | May 7, 2024 | 395 |
| NCT03651128Multiple Myeloma · United States, Belgium, Canada and more | 3 | Completed | Bristol-Myers Squibb | Apr 13, 2026 | 386 |
| NCT03384654Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, Belgium, France and more | 2 | Completed | Johnson & Johnson | Sep 22, 2022 | 47 |
| NCT03277105Multiple Myeloma · United States, Australia, Brazil and more | 3 | Completed | Johnson & Johnson | Jun 27, 2019 | 522 |
| NCT03234972Multiple Myeloma · China, Taiwan | 3 | Completed | Johnson & Johnson | Oct 7, 2019 | 213 |
| NCT03217812Multiple Myeloma · China, Hong Kong, Korea, Republic of and more | 3 | Completed | Johnson & Johnson | Jul 2, 2020 | 220 |
| NCT03201965Amyloidosis · United States, Australia, Belgium and more | 3 | Completed | Johnson & Johnson | Feb 14, 2020 | 416 |
| NCT03158688Multiple Myeloma · United States, Australia, Austria and more | 3 | Completed | Amgen | Jul 14, 2019 | 466 |
| NCT03011034Myelodysplastic Syndromes · United States, Belgium, Italy and more | 2 | Completed | Johnson & Johnson | Jan 23, 2019 | 34 |
| NCT02951819Multiple Myeloma · United States | 2 | Completed | Johnson & Johnson | Mar 8, 2018 | 101 |
| NCT02927925Lymphoma · China, Hong Kong, Korea, Republic of and more | 2 | Completed | Johnson & Johnson | Jan 2, 2020 | 32 |
| NCT02918331Multiple Myeloma · Japan | 1 | Completed | Johnson & Johnson | Oct 2017 | 7 |
| NCT02852837Multiple Myeloma · China | 1 | Completed | Johnson & Johnson | Dec 13, 2019 | 50 |
| NCT02807454Multiple Myeloma · United States, Belgium, Canada and more | 2 | Terminated | Bristol-Myers Squibb | Jan 3, 2022 | 37 |
| NCT02773030Multiple Myeloma · United States, Australia, Canada and more | 2 | Active, not recruiting | Bristol-Myers Squibb | May 9, 2024 | 466 |
| NCT02497378Multiple Myeloma · Japan | 1 | Completed | Johnson & Johnson | Mar 6, 2018 | 8 |
| NCT02413489Lymphoma, Mantle-Cell · United States, Australia, Belgium and more | 2 | Terminated | Johnson & Johnson | Jun 1, 2017 | 36 |
| NCT02316106Multiple Myeloma · United States, Australia, Canada and more | 2 | Completed | Johnson & Johnson | Jun 2, 2023 | 123 |
| NCT02252172Multiple Myeloma · United States, Australia, Austria and more | 3 | Completed | Johnson & Johnson | Sep 24, 2018 | 737 |
| NCT02195479Multiple Myeloma · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Nov 21, 2017 | 706 |
| NCT02136134Multiple Myeloma · United States, Australia, Brazil and more | 3 | Completed | Johnson & Johnson | Jan 11, 2016 | 498 |
| NCT02116569Multiple Myeloma · Japan | 1 | Completed | Johnson & Johnson | Sep 2015 | 9 |
| NCT02076009Multiple Myeloma · United States, Australia, Belgium and more | 3 | Completed | Johnson & Johnson | Mar 7, 2016 | 569 |
| NCT01985126Multiple Myeloma · United States, Canada, Spain | 2 | Completed | Johnson & Johnson | Jan 9, 2015 | 124 |
| NCT00574288Multiple Myeloma · United States, Denmark, Netherlands and more | 2 | Completed | Johnson & Johnson | Jan 9, 2015 | 104 |
How it is read
Names in the registry
- “Daratumumab”, 32 entries
- “daratumumab”, 3 entries
- “Daratumumab SC”, 3 entries
- “Daratumumab IV”, 2 entries
- “CT-P44(Daratumumab)”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 37 studies
- Amyloidosis, 2 studies
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 study
- Myelodysplastic Syndromes, 1 study
- Lymphoma, Mantle-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.